Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics Revenue

Iovance Biotherapeutics had revenue of $99.31M in the quarter ending June 30, 2026, with 65.65% growth. This brings the company's total for the last twelve months to $324.97M, up 34.55% year-over-year. In the year 2025, Iovance Biotherapeutics had annual revenue of $263.50M with 60.60% growth. That makes Iovance Biotherapeutics the 13,978th largest company in the world by revenue and 2,556th in the United States.

• Revenue (ttm): $324.97M
• Revenue Growth: +34.55%
• P/S Ratio: 11.18
• Revenue / Employee: $333,302
• Employees: 975
• Market Cap: 3.63B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Amtagvi 220.02M 83.5%
• Proleukin 43.48M 16.5%

By Geography

Chart

• United States 259.01M 98.3%
• Rest of World 4.49M 1.7%

Fiscal year ended Dec 31, 2025 See the full Iovance Biotherapeutics breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	263.50M	99.43M	60.60%
Dec 31, 2024	164.07M	162.88M	13,698.99%
Dec 31, 2023	1.19M	-	-
Dec 31, 2022	-	-	-
Dec 31, 2021	-	-	-

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Aug 6, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment and geography data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Nov 2, 2026

Data Sources Report a data error